London, UK July 30, 2019 – MarketsandMarkets recently interviewed Alfred Budillon, Chief Experimental Pharmacology Unit Department, Istituto Nazionale Tumori, Italy regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK.
Dr. Budillon graduated in Medicine and passed the Specialty Certification in Oncology at University Federico II, Naples, Italy. He obtained the PhD in Oncology from University G. D’Annunzio of Chieti, Italy, and a master’s degree in health economy, Management and Bioethics. Dr. Budillon is currently the chief of Experimental Pharmacology, National Cancer Institute G. Pascale, Naples, Italy. He is author of more than 130 publications.
Q. What is the most trending area of epigenetics currently?
A. EPidrug combination with immunotherapy for cancer treatment
Q. What are the recent developments and technological advancements?
A. Many, but I would say evaluate epigenetic alterations on liquid biopsies
Q. What are the key take away points from your presentation?
A. Hdac inhibitors cannot be considered pure anticancer drugs, at least in solid tumors where should rather use as biological modifiers to be combined with other treatment approach to potentiate antocancsr effects and prevent/revert mechanism of resistance
Q. Hope you had a chance to go through the attached agenda. Please share your feedback on the same, also do let us know which community would be moist benefitted by the agenda.
A. I think for the biopharma with epigenetics interest the agenda is quite interesting
Alfredo Budillon will present his insights on “Development of novel therapeutic anticancer approach with HDAC inhibitors: from the bench to the bedside”
The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register – https://bit.ly/2M8ol6u
For more inquiries contact Amit Shelke, Marketing Manager on email@example.com